Traders should monitor the upcoming earnings call for any material updates on financial performance, pipeline progress, or commercialization of the FDA EUA-authorized monoclonal antibody.
IVVD drugs
IVVD drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 3 $1.62entry
- T+1 · 9mo ago +5.56%α +4.79% · $1.71
- T+5 · 8mo ago +12.96%α +13.44% · $1.83
- T+20 · 8mo ago −19.75%α −15.35% · $1.30
- T+60 · 6mo ago −30.25%α −40.56% · $1.13
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Invivyd announced it will host a conference call on March 5, 2026, to discuss its Q4 and full-year 2025 financial results and provide a corporate update. The press release contains no financial data or material operational updates, serving only as a notification of the upcoming earnings event.
Key Facts
- Invivyd will host a conference call on March 5, 2026, at 8:30 a.m. ET.
- The call will cover Q4 and full-year 2025 financial results and a corporate update.
- No financial figures, guidance, or operational results were disclosed in the release.
- A webcast and replay will be available via the company’s investor relations website.
Financial Impact
No financial data disclosed
Risk Factors
- Lack of disclosed financials increases uncertainty ahead of the earnings call.
- Biotech stocks like IVVD can be volatile around earnings and regulatory updates.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3247875 |
Track record
19 reports on IVVD
3 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +35.85% at T+20 after the Jul 6, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 16, 2026today Press Release Neutral 6/10 Entry $0.5603 Now $0.5380 −3.98% settles Nov 23
- Nov 3, 202613d ago Press Release Neutral 2/10 Entry $0.5815 to $0.5744 Now $0.5380 −7.48% ▼ −1.22% −0.63% vs SPY
- Sep 29, 20266w ago 8-K Bullish 7/10 Entry $0.8501 to $0.8064 Now $0.5380 −36.71% ▼ −5.14% −7.09% vs SPY
- Sep 22, 20267w ago Institutional Cluster Mixed 3/10 Entry $0.9640 to $0.8501 Now $0.5380 −44.19% ▼ −11.82% −10.63% vs SPY
- Sep 1, 202610w ago 8-K Neutral 6/10 Entry $0.8800 to $0.7973 Now $0.5380 −38.86% ▼ −9.40% −9.48% vs SPY
- Aug 17, 202613w ago 144 Neutral 2/10 Entry $0.8680 to $0.9387 Now $0.5380 −38.02% ▲ +8.15% +8.35% vs SPY
- Jul 6, 202619w ago 8-K Bearish 6/10 Entry $0.8340 to $0.7834 Now $0.5380 +35.49% ▲ +6.07% +6.56% vs SPY
- Jun 16, 202621w ago Press Release Neutral 5/10 Entry $0.8918 to $0.9346 Now $0.5380 −39.67% ▲ +4.80% +7.03% vs SPY
- Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $0.8125 to $0.9312 Now $0.5380 −33.78% ▲ +14.61% +14.18% vs SPY
- Jun 9, 202622w ago Press Release Neutral 4/10 Entry $0.9900 to $0.8686 Now $0.5380 −45.66% ▼ −12.26% −14.67% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers